Fig. 5.

Pharmacological status of PDX models. In vivo pharmacological evaluation was performed by measuring the tumor volume in vehicle-treated and TKI-treated mice for: A. Two EGFR-resistant PDX models (MR7 and MR441) treated with 25 mg/kg of Osimertinib and vehicle. B. Two ALK-resistant PDX models (MR619, from cholangiocarcinoma, and MR448re, from lung) treated with 50 mg/kg of Alectinib and 20 mg/kg of Lorlatinib, respectively. C. Two FGFR3 bladder PDX models from the same patient: one from a biopsy in a stable disease site (MR86-SD) and one from a resistant disease site (MR86-PD), treated with 15 mg/kg of erdafitinib and vehicle. D. Two FGFR2-resistant cholangiocarcinoma PDX models (MR313 and MR369) treated with 1 mg/kg of Pemigatinib or vehicle